 The FDA scheduled their decision for May 25th of that year and twice postponed.The company received a Complete Response Letter from the agency on rintatolimod's NDA in December 2009, requesting further data.In 2007, and again during the 2009 swine flu pandemic, Carter said that rintatolimod could also be used as an H1N1 flu vaccine booster, citing in vitro studies with Ampligen and neuraminidase inhibitors oseltamivir and zanamivir (brand names Tamiflu and Relenza).